09:57 AM EST - Bausch Health Companies Inc. : Said its Bausch + Lomb division announced that Pr VYZULTA ® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension , now has expanded public drug program reimbursement in Alberta , Saskatchewan , Manitoba , New Brunswick , Nova Scotia , Newfoundland and Labrador and as part of the federal Non-Insured Health Benefits (NIHB). Bausch Health Companies Inc.
shares T.BHC are trading down $0.66 at $20.40.
